Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30286828 | 0.92 | OPRM1 (0.52) | OPRM1F2OPRD1ACENTSR2 | |
| SCHEMBL29886892 | 0.91 | OPRM1 (0.47) | OPRM1OPRD1 | |
| SCHEMBL30080797 | 0.90 | OPRM1 (0.51) | OPRM1F2OPRD1ACENTSR2 | |
| SCHEMBL20764559 | 0.90 | OPRM1 (0.52) | OPRM1F2OPRD1NTSR2NTSR1 | |
| SCHEMBL29591635 | 0.88 | OPRM1 (0.52) | OPRM1F2OPRD1ACENTSR2 | |
| SCHEMBL30434957 | 0.88 | OPRM1 (0.57) | OPRM1F2ACENTSR2NTSR1 | |
| SCHEMBL30435067 | 0.88 | OPRM1 (0.55) | OPRM1F2ACENTSR2NTSR1 | |
| SCHEMBL30723553 | 0.87 | OPRM1 (0.53) | OPRM1F2NTSR2NTSR1CXCR4 | |
| SCHEMBL30424443 | 0.87 | F2 (0.50) | OPRM1F2ACENTSR2NTSR1 | |
| SCHEMBL417518 | 0.86 | OPRM1 (0.45) | OPRM1NTSR2NTSR1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301858-A1 | DOSING OF SIRNA COMPOUNDS TO THE CISTERNA MAGNA | Alnylam Pharmaceuticals, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022187617-A9 | DOSING OF SIRNA COMPOUNDS TO THE CISTERNA MAGNA | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2022187617-A1 | DOSING OF SIRNA COMPOUNDS TO THE CISTERNA MAGNA | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |